Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab
Clinical trial NCT04013854 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04013854
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-01-01
- Primary completion
- 2026-08-01
- Enrollment
- 67
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.